Navigating Centene Skyrizi Prior Authorization for Risankizumab

Efficiently manage Centene Skyrizi prior authorization requests by understanding the payer's federated structure and specific submission pathways for risankizumab.

For revenue cycle directors and prior authorization coordinators, securing timely approvals for specialty medications like Skyrizi from Centene-affiliated health plans requires navigating a complex, decentralized system. This guide provides an operational overview of the Centene Skyrizi prior authorization process, highlighting key considerations for medical and pharmacy benefit submissions.

Understanding Skyrizi and Centene's Federated Prior Authorization Model

Skyrizi (risankizumab) is an IL-23 inhibitor used for conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease. Its high cost and specialty nature necessitate prior authorization. Centene Corporation operates through numerous state-licensed subsidiaries and national brands like Ambetter and Wellcare, each with distinct operational procedures for prior authorization, making a unified approach challenging.

Centene Prior Authorization Channels for Specialty Medications

Subsidiary-specific provider portals for medical benefit PAs.
X12 278 electronic submissions via clearinghouses for medical benefit.
Envolve Pharmacy Solutions for pharmacy benefit PAs.
CoverMyMeds and Surescripts ePA for retail pharmacy benefit.
Contracted specialty pharmacies for certain complex medications.

Formulary, Step Therapy, and Clinical Criteria for Skyrizi

Centene subsidiaries publish their own clinical policies and formularies. While specific formulary tiers, step therapy requirements, and quantity limits for Skyrizi vary by subsidiary and plan type (Medicaid, Ambetter, Wellcare), medical necessity criteria frequently reference InterQual guidelines or the NCCN compendium. For Medicaid lines, criteria must align with state Medicaid agency rules, which cannot be more restrictive than the state program's coverage.

Accessing Centene's Prior Authorization Policies for Risankizumab

There is no single "Centene medical policy library." Providers must consult the specific Centene subsidiary's provider portal for their market to access the relevant clinical policies and coverage determinations for Skyrizi. Verifying the policy number and effective date is crucial for accurate submission, and for Medicaid plans, understanding the layering of state Medicaid policy is essential.

Centene Skyrizi Prior Authorization Turnaround Times and CMS-0057-F

Prior authorization decision timeframes for Centene plans vary significantly. Medicaid lines adhere to state Medicaid agency mandates, while Wellcare and Allwell (Medicare Advantage) follow CMS-mandated organization determination timeframes (14 calendar days standard, 72 hours expedited). Many Centene entities, including Medicaid managed care, MA, CHIP, and Ambetter QHP-on-FFM lines, are impacted payers under CMS-0057-F, which phases in 72-hour standard and 24-hour expedited PA decision requirements.

Common Denial Reasons and Appeal Pathways for Skyrizi

Denials for Centene Skyrizi prior authorization requests often stem from medical necessity not met, insufficient documentation, prior authorization not obtained when required, or benefit exclusion. Appeal pathways are subsidiary-specific; Medicaid managed care appeals follow state-mandated processes, including fair hearing rights, while Medicare Advantage plans follow the CMS 5-level appeal structure for organization determinations.

Streamlining Centene Skyrizi Prior Authorization with Automation

Klivira integrates with EMRs and connects directly to payer portals and X12 278 channels, automating the submission and tracking of Centene Skyrizi prior authorizations. This reduces manual effort, helps ensure complete documentation, and supports adherence to varying subsidiary requirements and turnaround times, improving efficiency for specialty drug approvals.

Frequently asked questions

How do I find the specific prior authorization requirements for Skyrizi under a Centene health plan?

You must consult the provider portal of the specific Centene subsidiary (e.g., Fidelis Care, Health Net, Sunshine Health) that administers the member's plan. Each subsidiary publishes its own clinical policies and formularies, which detail the specific criteria for Skyrizi (risankizumab).

Is Skyrizi typically covered under the medical or pharmacy benefit for Centene members?

Coverage for Skyrizi can fall under either the medical or pharmacy benefit, depending on the specific Centene plan, the site of administration, and the method of dispensing. Injectable specialty medications may be routed through either, requiring careful verification of the member's benefit design and the relevant prior authorization channel.

What are common reasons for Centene Skyrizi prior authorization denials?

Common denial reasons include insufficient clinical documentation to support medical necessity, failure to meet step therapy requirements, prior authorization not being obtained before service, or the service/drug not being a covered benefit under the specific plan. Denials are often communicated via X12 277/835 or through the subsidiary's provider portal.

How do Centene's prior authorization turnaround times for Skyrizi differ across its plans?

Turnaround times vary significantly. Medicaid managed care plans adhere to state-specific mandates. Medicare Advantage plans (Wellcare, Allwell) follow CMS rules (14-day standard, 72-hour expedited). Many Centene lines are also subject to CMS-0057-F, phasing in 72-hour standard and 24-hour expedited decision timeframes.

Does Centene support electronic prior authorization (ePA) for Skyrizi?

For pharmacy benefit Skyrizi, Centene's Envolve Pharmacy Solutions and contracted PBMs generally support ePA via platforms like CoverMyMeds and Surescripts. For medical benefit Skyrizi, electronic submissions are typically via X12 278 or through subsidiary-specific provider portals, though corporate participation in Da Vinci interoperability initiatives suggests future expansion.